Nitrogen-containing tricyclic compounds and uses thereof in medicine

1. A compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof,

wherein:

T is —NH—, —O—, —S—, —C(═O)— or —CH 2 —;

each of X and Y is independently a bond, —O—, —S(═O) t —, —NR x —, —CR y R z — or —C(═O)—, or —X—Y— is —CHR h —CHR k — or —CR y ═CR z —;

each R x is independently hydrogen, deuterium, alkyl, aminoalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, halo-substituted aryl or arylalkyl;

each R y and R z is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkylamino, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, halo-substituted aryl or arylalkyl; or R y and R z together with the same carbon atom to which they are attached, independently and optionally form a cycloalkane ring or a heterocyclic ring, and wherein the cycloalkane ring and heterocyclic ring is independently and optionally substituted with substituents selected from F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, ethyl, isopropyl and trifluoromethyl;

each of R h and R k is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, ethyl, isopropyl or trifluoromethyl; or R h and R k , together with the carbon atoms to which they are attached, form a cycloalkane ring or a heterocyclic ring, wherein the cycloalkane ring and heterocyclic ring is independently and optionally substituted with substituents selected from F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, ethyl, isopropyl and trifluoromethyl;

each of R a and R b is independently hydrogen, deuterium or C 1-3 alkyl;

each R c is independently hydrogen, deuterium, F, Cl, Br, I, oxo, hydroxy, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, hydroxymethyl, aminomethyl, methylamino, dimethylamino, methoxymethyl, isopropoxymethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, phenyl, thiazolyl, thienyl, oxazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, —COOH, —C(═O)O—C 1-3 alkyl, —C(═O)NHS(═O) 2 —C 1-3 alkyl, —C(═O)NHS(═O) 2 -phenyl, —C(═O)NH—C 1-3 alkylene-S(═O) 2 OH, —C(═O)NH—C 1-3 alkylene-C(═O)OH, —S(═O) 2 NH 2 , —S(═O) 2 OH, —S(═O) 2 —C 1-3 alkyl, —C(═O)NH 2 or —C(═O)N(CH 3 ) 2 ;

each R 1 is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkylamino, haloalkoxy, alkoxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, halo-substituted aryl, arylalkyl, heteroaryl, -L 1 -C(═O)OR 8 , -L 1 -S(═O) t R 9 , —O-L 2 -C(═O)OR 8 , —O-L 2 -S(═O) t R 9 , —C(═O)NR 10 R 11 , —C(═O)N(R 10 )S(═O) 2 R 9 , —C(═NR 10 )NR 10 R 11 , —C(═O)N(R 10 )-L 3 -S(═O) 2 OR 8 , —C(═O)N(R 10 )C(═O)OR 8 or —C(═O)N(R 10 )-L 3 -C(═O)OR 8 ; or two adjacent R 1 , together with the ring atoms to which they are attached, independently and optionally form a carbocyclic ring, heterocyclic ring, aromatic ring or heteroaromatic ring, and wherein each R 1 is independently and optionally substituted with one or more R 12 ;

each R 8 is independently hydrogen, deuterium, alkyl, aminoalkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl or aryl;

each R 9 is independently hydrogen, deuterium, hydroxy, amino, alkyl, aminoalkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl or —NR 10 R 11 ;

each R 10 and R 11 is independently hydrogen, deuterium, alkyl, aminoalkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl or aryl; or R 10 and R 11 , together with the nitrogen atom to which they are attached, independently and optionally form a heterocyclic ring or heteroaromatic ring;

each R 12 is independently hydrogen, deuterium, F, Cl, Br, I, oxo, hydroxy, amino, nitro, cyano, alkyl, haloalkyl, alkoxy, alkylamino, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;

each L 1 is independently a bond, —NH—, —C(═O)—, C 1-3 alkylene, C 2-4 alkenylene or C 2-4 alkynylene;

each L 2 is independently C 1-3 alkylene, C 2-4 alkenylene or C 2-4 alkynylene;

each L 3 is independently a bond or C 1-3 alkylene;

Z is

each L is independently a bond, —O—, —S—, —NH—, —CH 2 —, —CH 2 —CH 2 —, —O—CH 2 —, —O—CH 2 —CH 2 — or —CH 2 —O—CH 2 —;

each R 2 , R 3 , R 4 , R 5 and R 6 is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy or C 1-3 haloalkoxy;

each R 7 is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 1-6 alkoxy-C 1-6 alkyl, C 3-6 cycloalkyl or C 2-6 heterocyclyl, and wherein the C 3-6 cycloalkyl and C 2-6 heterocyclyl is independently and optionally substituted with substituents selected from F, Cl, Br, I, hydroxy, amino, nitro and cyano;

m is 0, 1, 2, 3 or 4;

n is 0, 1 or 2; and

each t is independently 0, 1 or 2;

with the proviso that a compound having formula (I) is not:

2. The compound of claim 1 , wherein each R x is independently hydrogen, deuterium, C 1-6 alkyl, C 1-6 aminoalkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, C 2-6 heterocyclyl, phenyl, halo-substituted phenyl or benzyl;

each R y and R z is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 aminoalkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2-6 heterocyclyl, phenyl, halo-substituted phenyl or benzyl; or R y and R z together with the same carbon atom to which they are attached, independently and optionally form a C 3-6 cycloalkane ring or C 2-6 heterocyclic ring, and wherein the C 3-6 cycloalkane ring and C 2-6 heterocyclic ring is independently and optionally substituted with substituents selected from F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, ethyl, isopropyl and trifluoromethyl; and

each of R h and R k is independently methyl, ethyl, isopropyl or trifluoromethyl; or R h and R k together with the carbon atoms to which they are attached, form a C 3-6 cycloalkane ring or C 2-6 heterocyclic ring, and wherein the C 3-6 cycloalkane ring and C 2-6 heterocyclylic ring is independently and optionally substituted with substituents selected from F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, ethyl, isopropyl and trifluoromethyl.

3. The compound of claim 1 , wherein each R x is independently hydrogen, deuterium, methyl, ethyl, isopropyl, aminomethyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyclohexyl, tetrahydropyranyl, piperidinyl, phenyl, halo-substituted phenyl or benzyl;

each R y and R z is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, difluoromethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, hydroxymethyl, 2-hydroxyethyl, aminomethyl, methoxy, ethoxy, isopropoxy, t-butoxy, methylamino, dimethylamino, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, phenyl, halo-substituted phenyl or benzyl; or R y and R z , together with the same carbon atom to which they are attached, independently and optionally form cyclopropane, cyclobutane, cyclopentane, cyclohexane, azetidine, tetrahydrofuran, pyrrolidine, piperidine, piperazine, tetrahydropyran, morpholine or thiomorpholine, and wherein the cyclopropane, cyclobutane, cyclopentane, cyclohexane, azetidine, tetrahydrofuran, pyrrolidine, piperidine, piperazine, tetrahydropyran, morpholine and thiomorpholine is independently and optionally substituted with substituents selected from F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, ethyl, isopropyl and trifluoromethyl; and

each of R h and R k is independently methyl, ethyl, isopropyl or trifluoromethyl; or R h and R k , together with the carbon atoms to which they are attached, form cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, azetidinylene, tetrahydrofuranylene, pyrrolidinylene, piperidinylene, piperazinylene, tetrahydropyranylene, morpholinylene or thiomorpholinylene, and wherein the cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, azetidinylene, tetrahydrofuranylene, pyrrolidinylene, piperidinylene, piperazinylene, tetrahydropyranylene, morpholinyl and thiomorpholinyl is independently and optionally substituted with substituents selected from F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, ethyl, isopropyl and trifluoromethyl.

4. The compound of claim 1 , wherein each R 1 is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 aminoalkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 1-6 haloalkoxy, C 1-6 alkoxy-C 1-3 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, C 3-6 cycloalkyl-C 1-3 alkyl, C 2-6 heterocyclyl, C 2-6 heterocyclyl-C 1-3 alkyl, phenyl, halo-substituted phenyl, benzyl, C 1-5 heteroaryl, -L 1 -C(═O)OR 8 , -L 1 -S(═O) t R 9 , —O-L 2 -C(═O)OR 8 , —O-L 2 -S(═O) t R 9 , —C(═O)NR 10 R 11 , —C(═O)N(R 10 )S(═O) 2 R 9 , —C(═NR 10 )NR 10 R 11 , —C(═O)N(R 10 )-L 3 -S(═O) 2 OR 8 , —C(═O)N(R 10 )C(═O)OR 8 or —C(═O)N(R 10 )-L 3 -C(═O)OR 8 ; or two adjacent R 1 , together with the ring atoms to which they are attached, independently and optionally form a C 3-6 carbocyclic ring, C 2-6 heterocyclic ring, benzene ring or C 1-5 heteroaromatic ring, and wherein each the R 1 is independently and optionally substituted with one or more R 12 ;

each R 8 is independently hydrogen, deuterium, C 1-6 alkyl, C 1-6 aminoalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 2-6 haloalkyl, C 3-6 cycloalkyl, C 2-6 heterocyclyl or phenyl;

each R 9 is independently hydrogen, deuterium, hydroxy, amino, C 1-6 alkyl, C 1-6 aminoalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 2-6 haloalkyl, C 3-6 cycloalkyl, C 2-6 heterocyclyl, phenyl or —NR 10 R 11 ;

each R 10 and R 11 is independently hydrogen, deuterium, C 1-6 alkyl, C 1-6 aminoalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, C 2-6 heterocyclyl or phenyl; or R 10 and R 11 , together with the nitrogen atom to which they are attached, independently and optionally form a C 2-6 heterocyclic ring or C 1-5 heteroaromatic ring; and

each R 12 is independently hydrogen, deuterium, F, Cl, Br, I, oxo, hydroxy, amino, nitro, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2-6 heterocyclyl, phenyl or C 1-5 heteroaryl.

5. The compound of claim 1 , wherein each R 1 is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 aminoalkyl, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 haloalkoxy, C 1-3 alkoxy-C 1-3 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, C 3-6 cycloalkyl-C 1-3 alkyl, C 2-6 heterocyclyl, C 2-6 heterocyclyl-C 1-3 alkyl, phenyl, halo-substituted phenyl, benzyl, C 1-5 heteroaryl, -L 1 -C(═O)OR 8 , -L 1 -S(═O) t R 9 , —O-L 2 -C(═O)OR 8 , —O-L 2 -S(═O) t R 9 , —C(═O)NR 10 R 11 , —C(═O)N(R 10 )S(═O) 2 R 9 , —C(═NR 10 )NR 10 R 11 , —C(═O)N(R 10 )-L 3 -S(═O) 2 OR 8 , —C(═O)N(R 10 )C(═O)OR 8 or —C(═O)N(R 10 )-L 3 -C(═O)OR 8 ; or two adjacent R 1 , together with the ring atoms to which they are attached, independently and optionally form a C 3-6 carbocyclic ring, C 2-6 heterocyclic ring, benzene ring or C 1-5 heteroaromatic ring, and wherein each R 1 is independently and optionally substituted with one or more R 12 ;

each R 8 is independently hydrogen, deuterium, C 1-3 alkyl, C 1-3 aminoalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 2-4 haloalkyl, C 3-6 cycloalkyl, C 2-6 heterocyclyl or phenyl;

each R 9 is independently hydrogen, deuterium, hydroxy, amino, C 1-3 alkyl, C 1-3 aminoalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 2-4 haloalkyl, C 3-6 cycloalkyl, C 2-6 heterocyclyl, phenyl or —NR 10 R 11 ;

each R 10 and R 11 is independently hydrogen, deuterium, C 1-3 alkyl, C 1-3 aminoalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-3 haloalkyl, C 3-6 cycloalkyl, C 2-6 heterocyclyl or phenyl; or R 10 and R 11 , together with the nitrogen atom to which they are attached, independently and optionally form a C 2-6 heterocyclic ring or C 1-5 heteroaromatic ring; and

each R 12 is independently hydrogen, deuterium, F, Cl, Br, I, oxo, hydroxy, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 alkylamino, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, C 2-6 heterocyclyl, phenyl or C 1-5 heteroaryl.

6. The compound of claim 1 , wherein each R 1 is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, hydroxymethyl, aminomethyl, methylamino, dimethylamino, methoxylmethyl, isopropoxylmethyl, ethenyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, phenyl, thiazolyl, thienyl, oxazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, —COOH, —C(═O)O—C 1-3 alkyl, —C(═O)NHS(═O) 2 —C 1-3 alkyl, —C(═O)NHS(═O) 2 -phenyl, —C(═O)NH—C 1-3 alkylene-S(═O) 2 OH, —C(═O)NH—C 1-3 alkylene-C(═O)OH, —S(═O) 2 NH 2 , —S(═O) 2 OH, —S(═O) 2 —C 1-3 alkyl, —C(═O)NH 2 or —C(═O)N(CH 3 ) 2 ; wherein each R 1 is independently and optionally substituted with one or more R 12 ; and

each R 12 is independently hydrogen, deuterium, F, Cl, Br, I, oxo, hydroxy, amino, nitro, cyano, methyl, trifluoromethyl, methoxy, methylamino, vinyl, ethynyl, cyclopropyl, cyclohexyl, tetrahydrofuranyl, piperazinyl, phenyl or pyridinyl.

7. The compound of claim 1 , wherein each R 2 , R 3 , R 4 , R 5 and R 6 is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, isopropyl, difluoromethyl, trifluoromethyl, methoxy, isopropoxy, difluoromethoxy or trifluoromethoxy; and

each R 7 is independently hydrogen, deuterium, F, Cl, Br, I, hydroxy, amino, nitro, cyano, methyl, ethyl, isopropyl, t-butyl, hydroxymethyl, 2-hydroxyisopropyl, difluoromethyl, trifluoromethyl, 2-fluoroisopropyl, methoxy, isopropoxy, t-butoxy, dimethylamino, isopropoxymethyl, t-butoxymethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl;

wherein said cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl is independently and optionally substituted with substituents selected from F, Cl, Br, I, hydroxyl, amino, nitro and cyano.

8. A compound having one of the following structures:

or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising the compound of claim 1 , wherein the pharmaceutical composition optionally further comprises a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, or a combination thereof.

10. A method of managing, treating or lessening a disease mediated by FXR in a patient comprising administering to the patient a therapeutic effective amount of the compound of claim 1 , wherein the disease mediated by FXR is obesity, metabolic syndrome, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood level of fatty acid or glycerol, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, X syndrome, atherosclerosis, hypertension, acute anemia, neutropenia, dyslipidemia, type II diabetes, diabetic nephropathy, diabetic retinopathy, acute myocardial infarction, veno-occlusive disease, heart failure, peripheral aterial occlusive diseases, sexual dysfunction, stroke or thrombosis.

11. A method of managing, treating or lessening a disease mediated by FXR in a patient comprising administering to the patient a therapeutic effective amount of the pharmaceutical composition of claim 9 , wherein the disease mediated by FXR is obesity, metabolic syndrome, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood level of fatty acid or glycerol, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, X syndrome, atherosclerosis, hypertension, acute anemia, neutropenia, dyslipidemia, type II diabetes, diabetic nephropathy, diabetic retinopathy, acute myocardial infarction, veno-occlusive disease, heart failure, peripheral aterial occlusive diseases, sexual dysfunction, stroke or thrombosis.